Literature DB >> 8035532

Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10.

M Connors1, N A Giese, A B Kulkarni, C Y Firestone, H C Morse, B R Murphy.   

Abstract

In previous studies, children immunized with a formalin-inactivated respiratory syncytial virus vaccine (FI-RSV) developed severe pulmonary disease with greater frequency than did controls during subsequent natural RSV infection. In earlier efforts to develop an animal model for this phenomenon, extensive pulmonary histopathology developed in FI-RSV-immunized cotton rats and mice subsequently challenged with RSV. In mice, depletion of CD4+ T cells at the time of RSV challenge completely abrogated this histopathology. Furthermore, the predominant cytokine mRNA present in lungs of FI-RSV-immunized mice during subsequent infection with RSV was that characteristically secreted by Th2 T cells, namely interleukin-4 (IL-4). In the present studies, we sought to determine the relative contributions of gamma interferon (IFN-gamma), IL-2, IL-4, and IL-10 to the lymphocytic infiltration into the lungs observed following RSV challenge of mice previously immunized with FI-RSV. Mice previously immunized with FI-RSV or infected with RSV were depleted of IFN-gamma, IL-2, IL-4, or IL-10 immediately before RSV challenge, and the magnitude of inflammatory cell infiltration around bronchioles and pulmonary blood vessels was quantified. The phenomenon of pulmonary-histopathology potentiation by FI-RSV was reproduced in the present study, thereby allowing us to investigate the effect of cytokine depletion on the process. Simultaneous depletion of both IL-4 and IL-10 completely abrogated pulmonary histopathology in FI-RSV-immunized mice. Depletion of IL-4 alone significantly reduced bronchiolar, though not perivascular, histopathology. Depletion of IL-10 alone had no effect. Depletion of IFN-gamma, IL-2, or both together had no effect on the observed histopathology. These data indicate that FI-RSV immunization primes for a Th2-, IL-4-, and IL-10-dependent inflammatory response to subsequent RSV infection. It is possible that this process played a role in enhanced disease observed in infants and children immunized with FI-RSV.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8035532      PMCID: PMC236482     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

Review 1.  Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization.

Authors:  R M Chanock; R H Parrott; M Connors; P L Collins; B R Murphy
Journal:  Pediatrics       Date:  1992-07       Impact factor: 7.124

2.  Reinfection of mice with respiratory syncytial virus.

Authors:  B S Graham; L A Bunton; P F Wright; D T Karzon
Journal:  J Med Virol       Date:  1991-05       Impact factor: 2.327

3.  Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance.

Authors:  L Romani; S Mocci; C Bietta; L Lanfaloni; P Puccetti; F Bistoni
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

4.  Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo.

Authors:  F Powrie; S Menon; R L Coffman
Journal:  Eur J Immunol       Date:  1993-11       Impact factor: 5.532

5.  Defining protective responses to pathogens: cytokine profiles in leprosy lesions.

Authors:  M Yamamura; K Uyemura; R J Deans; K Weinberg; T H Rea; B R Bloom; R L Modlin
Journal:  Science       Date:  1991-10-11       Impact factor: 47.728

6.  Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice.

Authors:  B S Graham; L A Bunton; P F Wright; D T Karzon
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

7.  Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma.

Authors:  D S Robinson; Q Hamid; S Ying; A Tsicopoulos; J Barkans; A M Bentley; C Corrigan; S R Durham; A B Kay
Journal:  N Engl J Med       Date:  1992-01-30       Impact factor: 91.245

8.  In vivo induction of nitrite and nitrate by tumor necrosis factor, lymphotoxin, and interleukin-1: possible roles in malaria.

Authors:  K A Rockett; M M Awburn; B B Aggarwal; W B Cowden; I A Clark
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

9.  Messenger RNA expression of the cytokine gene cluster, interleukin 3 (IL-3), IL-4, IL-5, and granulocyte/macrophage colony-stimulating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects.

Authors:  A B Kay; S Ying; V Varney; M Gaga; S R Durham; R Moqbel; A J Wardlaw; Q Hamid
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

10.  Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosoma mansoni.

Authors:  E J Pearce; P Caspar; J M Grzych; F A Lewis; A Sher
Journal:  J Exp Med       Date:  1991-01-01       Impact factor: 14.307

View more
  116 in total

1.  Predominant type-2 response in infants with respiratory syncytial virus (RSV) infection demonstrated by cytokine flow cytometry.

Authors:  K Bendelja; A Gagro; A Bace; R Lokar-Kolbas; V Krsulovic-Hresic; V Drazenovic; G Mlinaric-Galinovic; S Rabatic
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

2.  Hepatitis B Virus Core Particles Containing a Conserved Region of the G Protein Combined with Interleukin-35 Protected Mice against Respiratory Syncytial Virus Infection without Vaccine-Enhanced Immunopathology.

Authors:  Jie Yang; Chen Ma; Yu Zhao; Anjing Fan; Xiufen Zou; Zishu Pan
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

3.  Effects of alveolar macrophage depletion on liposomal vaccine protection against respiratory syncytial virus (RSV).

Authors:  A Benoit; Y Huang; J Proctor; G Rowden; R Anderson
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

Review 4.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

5.  A critical role of Gas6/Axl signal in allergic airway responses during RSV vaccine-enhanced disease.

Authors:  Takehiko Shibata; Manabu Ato
Journal:  Immunol Cell Biol       Date:  2017-07-19       Impact factor: 5.126

Review 6.  A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza.

Authors:  Boopathy Ramakrishnan; Karthik Viswanathan; Kannan Tharakaraman; Vlado Dančík; Rahul Raman; Gregory J Babcock; Zachary Shriver; Ram Sasisekharan
Journal:  Trends Microbiol       Date:  2016-10-14       Impact factor: 17.079

7.  Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.

Authors:  J S Kahn; A Roberts; C Weibel; L Buonocore; J K Rose
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  Bacterial lysates improve the protective antibody response against respiratory viruses through Toll-like receptor 4.

Authors:  Silvina Coviello; Vera Wimmenauer; Fernando P Polack; Pablo M Irusta
Journal:  Hum Vaccin Immunother       Date:  2014-11-19       Impact factor: 3.452

9.  C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression.

Authors:  Guillermina A Melendi; Scott J Hoffman; Ruth A Karron; Pablo M Irusta; Federico R Laham; Alison Humbles; Brian Schofield; Chien-Hsiung Pan; Richard Rabold; Bhagvanji Thumar; Adeep Thumar; Norma P Gerard; Wayne Mitzner; Scott R Barnum; Craig Gerard; Steven R Kleeberger; Fernando P Polack
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

10.  Respiratory syncytial virus induces interleukin-10 by human alveolar macrophages. Suppression of early cytokine production and implications for incomplete immunity.

Authors:  J R Panuska; R Merolla; N A Rebert; S P Hoffmann; P Tsivitse; N M Cirino; R H Silverman; J A Rankin
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.